Genmab puts ChatGPT Enterprise into 2,000 hands
Biotech firm Genmab just expanded ChatGPT Enterprise across its entire organization, issuing over 2,000 licenses under its "AI Everywhere" initiative. Teams built over 100 custom GPTs to draft clinical trial documents and translate research, reporting an average time savings of 3.5 hours weekly. Why it matters: It shows frontier LLMs moving past generic productivity into complex, regulated biotech workflows.